v2.4.0.8

Collaboration Revenue - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  | 0 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  | 0 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  | 0 Months Ended |  | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended |  | 0 Months Ended | 3 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended |  | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 Upfront and Milestone Payments [Member] | Dec. 31, 2012 Upfront and Milestone Payments [Member] | Jan. 06, 2011 Ziopharm Oncology ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Oct. 24, 2012 Ziopharm Oncology ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Milestone One [Member] | Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2011 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Jan. 06, 2011 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Oct. 24, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member] | Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member] | Sep. 30, 2013 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member] | Dec. 31, 2012 Ziopharm Oncology ECC Unit of Accounting Two [Member] Upfront and Milestone Payments [Member] Milestone One [Member] | Jan. 06, 2011 Ziopharm Oncology ECC [Member] | Jan. 06, 2011 Ziopharm Oncology ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Oct. 24, 2012 Ziopharm Oncology ECC [Member] Upfront and Milestone Payments [Member] Milestone One [Member] | Sep. 30, 2013 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Dec. 31, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Dec. 31, 2011 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Mar. 21, 2012 Ziopharm Oncology ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2012 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2012 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2011 Synthetic Biologics Field One ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Synthetic Biologics Field Two ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Synthetic Biologics Field Two ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2012 Synthetic Biologics Field Two ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Synthetic Biologics [Member] Research and Development Services [Member] | Sep. 30, 2012 Synthetic Biologics [Member] Research and Development Services [Member] | Sep. 30, 2013 Synthetic Biologics [Member] Research and Development Services [Member] | Sep. 30, 2012 Synthetic Biologics [Member] Research and Development Services [Member] | Dec. 31, 2012 Synthetic Biologics [Member] Research and Development Services [Member] | Dec. 17, 2012 Synthetic Biologics [Member] Research and Development Services [Member] | Nov. 28, 2011 Elanco ECC [Member] | Nov. 28, 2011 Elanco ECC [Member] Maximum [Member] | Sep. 30, 2013 Elanco ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Elanco ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Elanco ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Elanco ECC [Member] Research and Development Services [Member] | Dec. 31, 2012 Elanco ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2012 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2012 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2012 Oragenics ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Jun. 05, 2012 Oragenics ECC [Member] | Jun. 05, 2012 Oragenics ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Oragenics ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Oragenics ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Oragenics ECC [Member] Research and Development Services [Member] | Sep. 30, 2012 Oragenics ECC [Member] Research and Development Services [Member] | Dec. 31, 2012 Oragenics ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Dec. 31, 2012 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Jun. 28, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Supplemental Upfront [Member] | Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Supplemental Upfront [Member] | Sep. 30, 2013 Fibrocell Science ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Supplemental Upfront [Member] | Oct. 05, 2012 Fibrocell Science ECC [Member] | Oct. 05, 2012 Fibrocell Science ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Fibrocell Science ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Fibrocell Science ECC [Member] Research and Development Services [Member] | Dec. 31, 2012 Fibrocell Science ECC [Member] Research and Development Services [Member] | Nov. 18, 2011 Synthetic Biologics Field One ECC [Member] | Nov. 18, 2011 Synthetic Biologics Field One ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Mar. 31, 2013 AmpliPhi ECC [Member] | Mar. 31, 2013 AmpliPhi ECC [Member] Maximum [Member] | Mar. 31, 2013 AmpliPhi ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 AmpliPhi ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 AmpliPhi ECC [Member] Research and Development Services [Member] | Mar. 31, 2013 AmpliPhi ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 AmpliPhi ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 AmpliPhi ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Mar. 31, 2013 Genopaver ECC [Member] | Mar. 31, 2013 Genopaver ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Genopaver ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Genopaver ECC [Member] Research and Development Services [Member] | Apr. 27, 2013 Soligenix ECC [Member] | Apr. 27, 2013 Soligenix ECC [Member] Maximum [Member] | Apr. 27, 2013 Soligenix ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Soligenix ECC [Member] Research and Development Services [Member] | Sep. 30, 2013 Soligenix ECC [Member] Research and Development Services [Member] | Feb. 14, 2013 AquaBounty ECC [Member] | Aug. 06, 2012 Synthetic Biologics Field Two ECC [Member] | Oct. 05, 2012 Synthetic Biologics Field Two ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Oragenics Second ECC [Member] | Sep. 30, 2013 Oragenics Second ECC [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Oragenics Second Ecc Unit Of Accounting One [Member] | Sep. 30, 2013 Genopaver ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Genopaver ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Soligenix ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member] | Sep. 30, 2013 Soligenix ECC Unit of Accounting One [Member] Upfront and Milestone Payments [Member] Upfront [Member]
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement consideration received, shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,636,926 | 3,636,926 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,392,425 |  |  |  |  |  |  |  |  | 1,243,781 |  |  |  | 1,317,520 |  |  |  |  | 3,123,558 |  |  | 24,000,000 |  |  |  |  |  |  |  |  |  |  |  | 1,034,483 |  |  |  |  | 3,552,210 |  | 1,348,000 |  |  |  |  |
Collaborative arrangement consideration received, value |  |  |  |  |  |  |  |  |  | $ 1,171 |  |  |  |  |  |  |  | $ 17,159 |  |  |  |  | $ 17,457 | $ 18,330 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,588 |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,576 |  |  |  |  | $ 1,687 |  |  | $ 2,400 |  |  | $ 2,400 |  |  |  | $ 3,000 |  |  |  |  | $ 1,331 |  |  |  |  | $ 7,815 |  | $ 3,503 |  |  |  |  |
Percent of shares outstanding at the date of achievement of future milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.495% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9.995% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of net profit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  | 90 days |  | 90 days |  |  |  |  |  |  |  | 90 days |  |  |  | 90 days |  |  |  |  |  | 90 days |  | 90 days |  |  |  |  |  |
Period when agreement cannot be voluntarily terminated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18 months |  |  |  |  |  |  |  |
Collaboration revenue | 6,028 | 2,904 | 16,566 | 7,163 | 13,706 | 5,118 |  |  | 1,115 |  | 314 | 314 | 942 | 943 | 1,257 | 1,257 |  | 2,420 | 330 | 990 | 220 |  |  |  | 2,122 | 2,137 | 5,843 | 5,095 | 6,333 | 2,724 |  | 33 | 1,535 | 97 | 130 | 22 | 163 | 489 | 163 | 176 | 71 | 865 | 194 | 327 |  |  |  | 90 | 51 | 289 | 485 | 587 | 138 | 137 | 412 | 182 | 320 |  |  | 344 | 137 | 1,057 | 137 | 516 | 158 | 474 | 158 |  | 169 | 169 |  |  | 1,383 | 2,428 | 61 |  |  |  |  |  | 128 | 162 |  | 54 | 109 |  |  | 315 | 528 |  |  |  | 13 | 13 |  |  |  |  |  |  | 68 | 136 | 30 | 50
Deferred revenue | 67,392 |  | 67,392 |  | 58,636 |  | 65,846 | 51,359 |  |  | 12,886 |  | 12,886 |  | 13,828 |  | 16,342 | 14,739 | 13,529 | 13,529 | 14,519 |  |  |  |  |  |  |  | 4,862 |  | 10,000 |  |  |  | 1,535 |  | 7,163 | 7,163 | 7,652 | 1,502 |  | 1,502 |  | 2,367 | 2,500 |  |  |  |  |  |  |  | 5,857 |  | 5,857 |  | 6,268 |  |  |  |  |  |  |  | 6,944 | 6,944 | 7,418 | 7,612 | 7,443 | 7,443 |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,291 | 2,291 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,459 | 2,864 | 2,864 | 1,281 | 1,281
Deferred revenue current | 7,398 |  | 7,398 |  | 9,963 | 1,402 |  |  |  |  |  |  |  |  | 1,257 |  |  |  |  |  | 1,320 |  |  |  |  |  |  |  |  |  |  |  |  |  | 130 |  |  |  | 651 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 549 |  |  |  |  |  |  |  |  |  | 631 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue for research and development services applied against the prepayment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,141 | 1,893 | 4,862 | 3,900 | 5,138 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 133 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Related party receivables | 4,538 |  | 4,538 |  | 531 | 272 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 981 |  | 981 |  |  | 215 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 220 |  | 220 |  | 270 |  |  |  |  |  |  |  |  | 1,041 | 1,041 | 61 |  |  |  |  |  | 67 | 67 |  |  |  |  |  | 241 | 241 |  |  |  | 13 | 13 |  |  |  |  |  |  |  |  |  |
Consideration to be received upon achievement of future milestone 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000 |  | 2,000 |  |  |  |  |  |
Consideration to be received upon achievement of future milestone 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000 |  | 5,000 |  |  |  |  |  |
Field expansion fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000 |  |  |  |  |  |  |  |
Aggregate consideration to be received upon achievement of future milestones per product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,250 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,500 |  |  |  |  |  |  |  |  |  |  |  | 7,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Required notice period for voluntary termination of collaboration agreement if services in progress |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 180 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade receivables | 195 |  | 195 |  | 141 | 20 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 91 |  | 91 |  | 102 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of shares outstanding at the date of achievement of future milestone 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of reverse stock split |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1-for-25 reverse stock split |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate of savings from improvement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Level of net sales at which royalty rate changes to tier 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maturity date of promissory note |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | December 31, 2013 |  |  |  |  |
Collaborative arrangement consideration received, value of convertible promissory note |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,956 |  |  |  |  |
Consideration to be received upon achievement of future milestone 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 |  |  |  |  |  |
Royalty rate as a percentage of gross profit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16.66% |  |  |  |  |  |  |  |  |

X
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 2 -Article 4 + Details
Name: | us-gaap_DueFromRelatedPartiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Description of the terms and manner of settlement of the related party transaction. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period at the beginning of the collaborative agreement during which the collaborative partner cannot voluntarily terminate the agreement. + References No definition available. + Details
Name: | xon_CollaborationAgreementPeriodWhenVoluntaryTerminationIsNotAllowed
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | xon_CollaborationAgreementsLineItems
Namespace Prefix: | xon_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notice period required for voluntary termination by collaborative partner of collaborative agreement. + References No definition available. + Details
Name: | xon_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration agreement termination notice period if services in progress. + References No definition available. + Details
Name: | xon_CollaborationAgreementTerminationNoticePeriodIfServicesInProgress
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized from contractual agreements with collaborative partners where the entity receives payments for research and development and/or manufacturing services, as provided for in the agreements, and recognizes deferred revenues from contractual upfront and milestone payments from the partners. + References No definition available. + Details
Name: | xon_CollaborationRevenues
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative agreement aggregate future milestone consideration per product. + References No definition available. + Details
Name: | xon_CollaborativeAgreementAggregateFutureMilestoneConsiderationPerProduct
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative agreement field expansion fee. + References No definition available. + Details
Name: | xon_CollaborativeAgreementFieldExpansionFee
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percent of shares outstanding at the date of achievement of a future milestone, representing maximum range of shares to which the entity is entitled to receive upon achievement of said milestone. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingShares
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement additional consideration receivable as percentage of outstanding shares five. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFive
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement additional consideration receivable as percentage of outstanding shares four. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesFour
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement additional consideration receivable as percentage of outstanding shares three. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesThree
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement additional consideration receivable as percentage of outstanding shares two. + References No definition available. + Details
Name: | xon_CollaborativeArrangementAdditionalConsiderationReceivableAsPercentageOfOutstandingSharesTwo
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative arrangement consideration received shares. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedShares
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement consideration received value. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement Consideration Received Value of Convertible Promissory Note + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement net sales at which royalty rate changes to tier two. + References No definition available. + Details
Name: | xon_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative arrangement royalties as percentage of net sales tier one. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement royalties as percentage of net sales tier two. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement royalty rate as percentage of gross profit. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfGrossProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rate of royalty payments due to entity under terms of collaborative arrangement, represented as a percentage of net profit. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement royalty rate as percentage of savings from improvement. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfSavingsFromImprovement
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future milestone payment one. + References No definition available. + Details
Name: | xon_FutureMilestonePaymentOne
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Future Milestone Payment Three + References No definition available. + Details
Name: | xon_FutureMilestonePaymentThree
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Future milestone payment two. + References No definition available. + Details
Name: | xon_FutureMilestonePaymentTwo
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenues applied towards prepayment research and development services. + References No definition available. + Details
Name: | xon_RevenuesAppliedTowardsPrepaymentResearchAndDevelopmentServices
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reverse stock split ratio on common stock. + References No definition available. + Details
Name: | xon_ReverseStockSplitRatioOnCommonStock
Namespace Prefix: | xon_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant